On January 11, 2026, during J.P. Morgan Healthcare Week, the American Healthcare Executive Association (AHEA) convened senior leaders from across global biopharma in San Francisco for the 2026 Global Biopharma Leadership Forum — creating a trusted platform for strategic exchange ahead of the industry’s most influential gathering of the year.

Hosted at the San Francisco office of Jones Day in collaboration with MSQ Ventures, the Forum brought together executives, investors, and innovators to explore global strategy, cross-border transactions, and the growing role of AI in drug development — reflecting an industry increasingly shaped by China–Asia connectivity and multinational pharma engagement.

We extend our sincere appreciation to Echo Hindle-Yang, CEO of MSQ Ventures, and Tony Chen, Partner at Jones Day, for their partnership in enabling a candid, high-level dialogue among decision-makers across regions and disciplines.

We were also honored to have Blair Bu, Secretary of AHEA, deliver the opening remarks, underscoring the importance of sustained cross-border dialogue, execution-driven collaboration, and leadership alignment in today’s global biopharma environment.

American Healthcare Executive Association and IntelliPro were pleased to engage with peers on these timely and strategic discussions.

Key Insights from the Forum:

🔹 Multinational pharma remains the anchor buyer in cross-border transactions· Strategic interest continues to focus on China- and Asia-originated innovation — particularly assets designed from the outset for global clinical and regulatory pathways.

🔹 The market has shifted decisively toward quality and execution· Best-in-class science, clear translational logic, and globally scalable development plans are now prioritized — resulting in fewer but higher-conviction transactions.

🔹 China–Asia innovation is increasingly global by design· Early alignment with FDA/EMA standards, global trial strategies, and international partnering frameworks are becoming standard practice.

🔹 AI has become core infrastructure· From discovery through clinical execution and portfolio decision-making, AI is now embedded as a foundational capability driving speed, precision, and capital efficiency.

🔹 Cross-border capital remains active — with greater discipline· Valuations, deal structures, and governance models reflect a more measured environment, emphasizing milestone-based economics, risk-sharing, and long-term strategic alignment.

We sincerely appreciate the thoughtful contributions from our speakers, presenting companies, and participants, and look forward to continuing the dialogue as global biopharma moves toward a more execution-driven, innovation-led, and globally integrated future.